RU2007141999A - MEDICINE - Google Patents
MEDICINE Download PDFInfo
- Publication number
- RU2007141999A RU2007141999A RU2007141999/15A RU2007141999A RU2007141999A RU 2007141999 A RU2007141999 A RU 2007141999A RU 2007141999/15 A RU2007141999/15 A RU 2007141999/15A RU 2007141999 A RU2007141999 A RU 2007141999A RU 2007141999 A RU2007141999 A RU 2007141999A
- Authority
- RU
- Russia
- Prior art keywords
- drug according
- metacin
- methyl
- caffeine
- ondansetron
- Prior art date
Links
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract 12
- 229940079593 drug Drugs 0.000 claims abstract 10
- 239000003814 drug Substances 0.000 claims abstract 10
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims abstract 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract 6
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract 6
- 229960001948 caffeine Drugs 0.000 claims abstract 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract 6
- 229960005343 ondansetron Drugs 0.000 claims abstract 6
- 239000002552 dosage form Substances 0.000 claims abstract 4
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims abstract 2
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000000069 prophylactic effect Effects 0.000 claims abstract 2
- 230000005855 radiation Effects 0.000 claims abstract 2
- 230000001052 transient effect Effects 0.000 claims abstract 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Лекарственное средство, обладающее профилактическим действием для купирования первичной реакции на облучение и ранней преходящей недееспособности, содержащее ондансетрон и метацин, отличающееся тем, что дополнительно введен фармакологически активный агент кофеин в массовом соотношении ондансетрон:метацин:кофеин 4:1:20÷300. ! 2. Лекарственное средство по п.1, отличающееся тем, что оно представляет собой таблетированную лекарственную форму. ! 3. Лекарственное средство по любому из пп.1-2, отличающееся тем, что оно представляет собой таблетированную лекарственную форму, покрытую оболочкой. ! 4. Лекарственное средство по любому из пп.1-2, отличающееся тем, что 1,2,3,9-тетрагидро-9-метил-3-[(2-метил-1Н-имидазол-1-ил)метил]-4Н-карбазол-4-он используют в виде хлоргидрата дигидрата. ! 5. Лекарственное средство по любому из пп.1-2, отличающееся тем, что ондансетрон:метацин:кофеин используют в весовом соотношении 4:1:50÷100.1. A drug with a prophylactic effect for stopping the primary reaction to radiation and early transient disability, containing ondansetron and metacin, characterized in that the pharmacologically active agent caffeine is additionally introduced in a mass ratio of ondansetron: metacin: caffeine 4: 1: 20 ÷ 300. ! 2. The drug according to claim 1, characterized in that it is a tablet dosage form. ! 3. The drug according to any one of claims 1 to 2, characterized in that it is a tablet coated dosage form. ! 4. The drug according to any one of claims 1 to 2, characterized in that 1,2,3,9-tetrahydro-9-methyl-3 - [(2-methyl-1H-imidazol-1-yl) methyl] - 4H-carbazol-4-one is used as the dihydrate hydrochloride. ! 5. The drug according to any one of claims 1 to 2, characterized in that ondansetron: metacin: caffeine is used in a weight ratio of 4: 1: 50 ÷ 100.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007141999/15A RU2363463C1 (en) | 2007-11-14 | 2007-11-14 | Medicinal agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007141999/15A RU2363463C1 (en) | 2007-11-14 | 2007-11-14 | Medicinal agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007141999A true RU2007141999A (en) | 2009-05-20 |
| RU2363463C1 RU2363463C1 (en) | 2009-08-10 |
Family
ID=41021408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007141999/15A RU2363463C1 (en) | 2007-11-14 | 2007-11-14 | Medicinal agent |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2363463C1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60156446A (en) * | 1984-01-26 | 1985-08-16 | 而至歯科工業株式会社 | Reinforcement of pottery tooth |
| GB2325409B (en) * | 1994-06-28 | 1999-02-10 | Kenneth Francis Prendergast | Pharmaceutical use of ondansetron/cyclodextrin complexes |
| GB9423511D0 (en) * | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| RU2185825C1 (en) * | 2001-03-12 | 2002-07-27 | Государственный научный центр - Институт биофизики | Pharmaceutical composition containing ondansetron and methacine |
| RU2229882C2 (en) * | 2002-04-05 | 2004-06-10 | Научно-производственный центр "Фармзащита" | Medicinal agent |
| RU2234315C1 (en) * | 2003-06-30 | 2004-08-20 | Государственный научный центр - Институт биофизики | Pharmaceutical composition comprising ondansetron, methacine and benzamide |
-
2007
- 2007-11-14 RU RU2007141999/15A patent/RU2363463C1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2363463C1 (en) | 2009-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012024019A2 (en) | controlled release dosage form and method for releasing a drug | |
| PE20130524A1 (en) | PARENTERAL PHARMACEUTICAL FORM, RELEASING AROMATASE AND GESTAGEN INHIBITORS FOR THE TREATMENT OF ENDOMETROSIS | |
| CL2010001358A1 (en) | Pharmaceutical composition comprising a pharmaceutically acceptable vehicle and a combination of two doses of pramipexole and rasagiline, wherein the fixed dose combination contains from 0.06 to less than 1.5 mg of pramipexole and from 0.05 mg to less than 1 , 0 mg rasagiline. | |
| CL2012000754A1 (en) | Compounds derived from benzoxazepine condensed with pyrazolyl or imidazolyl, inhibitors of pi3 kinase activity; pharmaceutical composition comprising a compound; and its use in the preparation of drugs for the treatment of cancer. | |
| MX2009003372A (en) | Non-mucoadhesive film dosage forms. | |
| MX343867B (en) | Methods for administering weight loss medications. | |
| CL2009000662A1 (en) | Trisubstituted 1,2,4-triazole derivative compounds, modulators of the nicotinic acetylcholine receptor; pharmaceutical composition; its preparation process; and use for the prevention or treatment of psychotic disorders, intellectual impairment disorders or diseases, or inflammatory diseases or disorders. | |
| MX2010007609A (en) | Capsule formulation. | |
| NO20070719L (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, process for its preparation and use thereof | |
| JO3019B1 (en) | Trisubstituted 1,2,4-Triazoles | |
| CL2011001860A1 (en) | Compounds derived from indole; preparation process of said compounds; pharmaceutical composition and combination; and use in the treatment of cancer. | |
| NZ596064A (en) | Fixed dose drug combination formulations | |
| AR077284A1 (en) | SOLID PHARMACEUTICAL FIXED DOSAGE COMPOSITIONS INCLUDING IRBESARTAN AND AMLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION | |
| PH12014502331B1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| PH12012501965A1 (en) | Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan | |
| CL2011000625A1 (en) | Solid preparation comprising 2-ethoxy-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1h-benzimidazole (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl carboxylate, a ph regulating agent and a calcium antagonist compound; and methods for using and improving dissolution of the compound in the solid preparation. | |
| JOP20220160A1 (en) | Compounds active towards nuclear receptors | |
| CL2008003383A1 (en) | Compounds derived from (spiro piperidin) -benzamide, inhibitors of the equilibrative nucleoside transporter ent1; pharmaceutical composition comprising one of the compounds; process for preparing the composition; and process for preparing the compounds, useful for acute and chronic pain treatment. | |
| EP2540294A4 (en) | SOLID RELEASE PREPARATION FOR ORAL USE | |
| RU2006117790A (en) | APPLICATION OF A PYRAZOLE DERIVATIVE FOR THE PRODUCTION OF A MEDICINE SUITABLE FOR PREVENTION AND TREATMENT OF DYSLIPIDEMIA AND DISEASES ASSOCIATED WITH DYSLIPIDEMIA AND / OR OBESITY | |
| RU2007141999A (en) | MEDICINE | |
| EA201070715A1 (en) | DOSING MODES, PHARMACEUTICAL COMPOSITIONS AND PACKAGES FOR EMERGENCY CONTRACEPTION | |
| AR038858A1 (en) | COMBINATION | |
| GEP201706743B (en) | Oral formulation for the treatment of cardiovascular diseases | |
| TR200301553A1 (en) | New oral pharmaceutical formulations containing irbesartan active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20200416 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201115 |